|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Moon C, Park JC, Chae YK, Yun JH and Kim
S: Current status of experimental therapeutics for prostate cancer.
Cancer Lett. 266:116–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petrylak DP: Docetaxel (Taxotere) in
hormone-refractory prostate cancer. Semin Oncol. 27:24–29.
2000.PubMed/NCBI
|
|
4
|
Seruga B, Ocana A and Tannock IF: Drug
resistance in metastatic castration-resistant prostate cancer. Nat
Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Linn DE, Yang X, Sun F, et al: A Role for
OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells.
Genes Cancer. 1:908–916. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu K, Xie D, Zou Y, et al: The mechanism
of DAB2IP in chemo-resistance of prostate cancer cells. Clin Cancer
Res. 19:4740–4749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pevny LH and Lovell-Badge R: Sox genes
find their feet. Curr Opin Genet Dev. 7:338–344. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wegner M: From head to toes: the multiple
facets of Sox proteins. Nucleic Acids Res. 27:1409–1420. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kamachi Y, Uchikawa M and Kondoh H:
Pairing SOX off: with partners in the regulation of embryonic
development. Trends Genet. 16:182–187. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Masui S, Nakatake Y, Toyooka Y, et al:
Pluripotency governed by Sox2 via regulation of Oct3/4 expression
in mouse embryonic stem cells. Nat Cell Biol. 9:625–635. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fong H, Hohenstein KA and Donovan PJ:
Regulation of self-renewal and pluripotency by Sox2 in human
embryonic stem cells. Stem Cells. 26:1931–1938. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takahashi K, Tanabe K, Ohnuki M, et al:
Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell. 131:861–872. 2007. View Article : Google Scholar
|
|
13
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamanaka S: Strategies and new
developments in the generation of patient-specific pluripotent stem
cells. Cell Stem Cell. 1:39–49. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ben-Porath I, Thomson MW, Carey VJ, et al:
An embryonic stem cell-like gene expression signature in poorly
differentiated aggressive human tumors. Nat Genet. 40:499–507.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gangemi RM, Griffero F, Marubbi D, et al:
Sox2 silencing in glioblastoma tumor-initiating cells causes stop
of proliferation and loss of tumorigenicity. Stem Cells. 27:40–48.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bass AJ, Watanabe H, Mermel CH, et al:
Sox2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Güre AO, Stockert E, Scanlan MJ, et al:
Serological identification of embryonic neural proteins as highly
immunogenic tumor antigens in small cell lung cancer. Proc Natl
Acad Sci USA. 97:4198–4203. 2000.PubMed/NCBI
|
|
19
|
Hussenet T, Dali S, Exinger J, et al: SOX2
is an oncogene activated by recurrent 3q26.3 amplifications in
human lung squamous cell carcinomas. PLoS One. 5:e89602010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ye F, Li Y, Hu Y, Zhou C, Hu Y and Chen H:
Expression of Sox2 in human ovarian epithelial carcinoma. J Cancer
Res Clin Oncol. 137:131–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jia X, Li X, Xu Y, et al: SOX2 promotes
tumorigenesis and increases the anti-apoptotic property of human
prostate cancer cell. J Mol Cell Biol. 3:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saigusa S, Tanaka K, Toiyama Y, et al:
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their
association with distant recurrence after chemoradiotherapy. Ann
Surg Oncol. 16:3488–3498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao GH, Liu HM, Li BW, et al:
Establishment of a human colorectal cancer cell line P6C with stem
cell properties and resistance to chemotherapeutic drugs. Acta
Pharmacol Sin. 34:793–804. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian T, Zhang Y, Wang S, Zhou J and Xu S:
Sox2 enhances the tumorigenicity and chemoresistance of cancer
stem-like cells derived from gastric cancer. J Biomed Res.
26:336–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gen Y, Yasui K, Nishikawa T and Yoshikawa
T: SOX2 promotes tumor growth of esophageal squamous cell carcinoma
through the AKT/mammalian target of rapamycin complex 1 signaling
pathway. Cancer Sci. 104:810–816. 2013. View Article : Google Scholar
|
|
26
|
Kregel S, Kiriluk KJ, Rosen AM, et al:
Sox2 is an androgen receptor-repressed gene that promotes
castration-resistant prostate cancer. PLoS One. 8:e537012013.
View Article : Google Scholar
|
|
27
|
Kim SH, Juhnn YS and Song YS: Akt
involvement in paclitaxel chemoresistance of human ovarian cancer
cells. Ann N Y Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fraser M, Leung B, Jahani-Asl A, Yan X,
Thompson WE and Tsang BK: Chemoresistance in human ovarian cancer:
the role of apoptotic regulators. Reprod Biol Endocrinol. 1:662003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Smith DA, Kiba A, Zong Y and Witte ON:
Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway
to promote aggressive prostate malignancy in mouse and human
tissues. Mol Cancer Res. 11:1159–1165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Barile E, De SK, Feng Y, et al: Synthesis
and SAR studies of dual AKT/NF-kappaB inhibitors against melanoma.
Chem Biol Drug Des. 82:520–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu L, Hofmann J, Lu Y, Mills GB and Jaffe
RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy
of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer
Res. 62:1087–1092. 2002.
|
|
32
|
Alimonti A, Carracedo A, Clohessy JG, et
al: Subtle variations in Pten dose determine cancer susceptibility.
Nat Genet. 42:454–458. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Trotman LC, Niki M, Dotan ZA, et al: Pten
dose dictates cancer progression in the prostate. PLoS Biol.
1:E592003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Makhov PB, Golovine K, Kutikov A, et al:
Modulation of Akt/mTOR signaling overcomes sunitinib resistance in
renal and prostate cancer cells. Mol Cancer Ther. 11:1510–1517.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang CC, Aronstam RS, Chen DR and Huang
YW: Oxidative stress, calcium homeostasis, and altered gene
expression in human lung epithelial cells exposed to ZnO
nanoparticles. Toxicol In Vitro. 24:45–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang S, Zu Y, Fu Y, Zhang Y and Efferth
T: Activation of the mitochondria-driven pathway of apoptosis in
human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel
derivative, 7-xylosyl-10-deacetylpaclitaxel. Int J Oncol.
33:103–111. 2008.
|
|
38
|
Lin F, Lin P, Zhao D, et al: Sox2 targets
cyclinE, p27 and survivin to regulate androgen-independent human
prostate cancer cell proliferation and apoptosis. Cell Prolif.
45:207–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang YI, Lee KT, Park HJ, et al:
Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer
cells through downregulation of the Akt and NFκB pathway.
Carcinogenesis. 33:2488–2498. 2012.PubMed/NCBI
|
|
41
|
Bae KM, Su Z, Frye C, et al: Expression of
pluripotent stem cell reprogramming factors by prostate tumor
initiating cells. J Urol. 183:2045–2053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sherr CJ: G1 phase progression: cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Altieri DC and Marchisio PC: Survivin
apoptosis: an interloper between cell death and cell proliferation
in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
|
|
44
|
Peng XH, Karna P, Cao Z, Jiang BH, Zhou M
and Yang L: Cross-talk between epidermal growth factor receptor and
hypoxia-inducible factor-1alpha signal pathways increases
resistance to apoptosis by up-regulating survivin gene expression.
J Biol Chem. 281:25903–25914. 2006. View Article : Google Scholar
|
